Evidence for erythropoietin as a molecular targeting agent

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 145-154

  Leyland Jones, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; JANUS KINASE; JANUS KINASE 2; PHOSPHOINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; CANCER CELL; CELL TYPE; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; ERYTHROID CELL; HUMAN; HYPOXIA; LIVER; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

EID: 0036319454     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70138-3     Document Type: Conference Paper

References (106)

1. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: Results from a prospective community oncology study
2. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients
3. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
4. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
5. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells
6. Erythropoietin
7. The molecular mechanism of erythropoietin action
8. Erythropoietin: Structure, control of production, and function
9. Homodimerization and constitutive activation of the erythropoietin receptor
10. Proliferation of multipotent hematopoietic cells controlled by a truncated erythropoietin receptor transgene
11. Erythropoietin receptor signals both proliferation and erythroid-specific differentiation
12. Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT I and STAT 5 in erythroid cells
13. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: A mechanism for controlled rates of erythrocyte production
14. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness
15. Human erythropoietin receptor: Cloning, expression, and biologic characterization
16. Expression of the erythropoietin gene
17. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver
18. Erythropoietin gene expression in human, monkey and murine brain
19. Erythropoietin and erythropoietin receptor in the developing human central nervous system
20. Erythropoietin receptor expression in human melanoma cells
21. Erythropoietin and erythropoietin receptor expression in human cancer
22. The negative impact of anemia on radiotherapy and chemoradiation outcomes
23. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anemia
24. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anemic nude mice
25. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect
26. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors
27. New insights into anti-HER-2 receptor monoclonal antibody research
28. Cytokine signaling through nonreceptor protein tyrosine kinases
29. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells
30. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction
31. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in interferon-gamma signal transduction pathway
32. The Jak-Stat pathway in normal and perturbed hematopoiesis
33. STATs and gene regulation
34. JAK 2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin
35. Molecular mechanisms of erythropoietin signaling
36. The erythropoietin receptor
37. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT
38. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways
39. Mouse oncostatin M: An immediate early gene induced by multiple cytokines through the JAK-STAT 5 pathway
40. Erythropoietin receptor and STAT5-specific pathways promote SKT 6 cell hemoglobinization
41. Erythropoietin activates Rafl by an Shc-independent pathway in CTLL-EPO-R cells
42. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways
43. Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway
44. Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein
45. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor
46. Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation
47. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT 7 erythroleukemia cells
48. Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3
49. Erythropoietin induces the association of phosphatidylinositol 3′-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor
50. Phosphatidylinositol 3-kinase associates, via its Src homology 2 domains, with the activated erythropoietin receptor
51. Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain
52. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, inhibits erythropoietin-induced erythroid differentiation of K562 cells
53. Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin responsive cells
54. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat 5 pathway
55. Physical and functional interaction between p72(syk) and erythropoietin receptor
56. Activation of hematopoietic progenitor kinase-1 by erythropoietin
57. Erythropoietin induces tyrosine phosphorylation and activation of phospholipase C-gammal in a human erythropoietin-dependent cell line
58. Tyrosine 425 within the activated erythropoietin receptor binds Syp, reduces the erythropoietin required for Syp tyrosine phosphorylation, and promotes mitogenesis
59. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells
60. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins
61. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase
62. Rapid activation by erythropoietin of protein kinase C in nuclei of erythroid progenitor cells
63. Signal transduction by the erythropoietin receptor: Evidence for the activation of phospholipases A2 and C
64. The role of cAMP and calcium in the stimulation of proliferation of immature erythroblasts by erythropoietin
65. Role of pertussis toxin sensitive guanosine triphosphate-binding proteins in the response of erythroblasts to erythropoietin
66. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway
67. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase
68. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells
69. Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein
70. Association of erythroid transcription factors: Complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1
71. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL
72. Coordinate expression and developmental role of Id2 protein and TAL/E2A heterodimer in erythroid progenitor differentiation
73. Expression of SCL is normal in transfusion-dependent Diamond-Blackfan anemia but other bHLH proteins are deficient
74. NF-κB transcription factors are involved in normal erythropoiesis
75. Bcl-3 expression and nuclear translocation are induced by GM-CSF and Epo in proliferating human erythroid precursors
76. Regulation of the erythroid Kruppel-like factor (EKLF) gene promoter by the erythroid transcription factor GATA-1
77. Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors
78. c-myc expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells
79. Erythropoietin activation of AP1 (Fos/Jun)
80. Towards a novel classification of human malignancies based on gene expression patterns
81. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
82. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction
83. Comparative features of comedo and noncomedo ductal carcinoma in situ of the breast on fine-needle aspiration biopsy
84. Carcinoma arising in microglandular adenosis: An immunohistochemical analysis of 20 intraepithelial and invasive neoplasms
85. Exploring the metabolic and genetic control of gene expression on a genomic scale
86. The transcriptional program in the response of human fibroblasts to serum
87. Molecular portraits of human breast tumours
88. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia
89. Localization of specific erythropoietin binding sites in defined areas of the mouse brain
90. Detection of erythropoietin in human liquor: Intrinsic erythropoietin production in the brain
91. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells
92. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death
93. Neurons and astrocytes express EPO mRNA: Oxygen-sensing mechanisms that involve the redox-state of the brain
94. Temporal profile of neuronal damage in a model of transient forebrain ischemia
95. Hypoxia-inducible factor 1α (HIF-1 α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions
96. Regulation of hypoxia inducible factor la is mediated by an oxygen-dependent domain via the ubiquitin-proteasome pathway
97. In vivo evidence that erythropoietin protects neurons from ischemic damage
98. A potential role for erythropoietin in focal permanent cerebral ischemia in mice
99. Human bloodbrain barrier insulin-like growth factor receptor
100. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels
101. Human bloodbrain barrier transferrin receptor
102. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
103. Cognitive function after systemic therapy for breast cancer
104. Cognitive function in breast cancer patients receiving adjuvant chemotherapy
105. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function
106. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review